Oncology Clinical Trials in Grand Rapids, MI

As of August 2026, 178 paid clinical trials are recruiting for Oncology in Grand Rapids, Michigan. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: August 31, 2026.

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

180 clinical trials for Oncology

·Clear filters·

Email me when a new oncology trial opens in Grand Rapids, MI.

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

for Rhabdomyosarcoma

Sites in Grand Rapids, Wyoming +83 more locations

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 50

Code: NCT07466316·Phase 3·Recruiting·Listed Mar 2026

Apply to this trial

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

for Gastric Cancer

Drug: Sonesitatug vedotin

Sites in Grand Rapids +71 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07431281·Phase 3·Recruiting·Listed Feb 2026

Apply to this trial

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

for Small Cell Lung Cancer

Drug: ABBV-706

Sites in Grand Rapids +29 more locations

Sponsor: AbbVie

Sex: All·Age: 18+

Code: NCT07365241·Phase 3·Recruiting·Listed Jan 2026

Apply to this trial

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

for Neoplasms

Drug: Nivolumab

Sites in Grand Rapids +4 more locations

Sponsor: Corcept Therapeutics

Sex: All·Age: 18+

Code: NCT07276373·Phase 1, Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

for Prostate Cancer

Sites in Grand Rapids +4 more locations

Sponsor: AstraZeneca

Sex: Male·Age: 18+

Code: NCT07192614·Phase 1, Phase 2·Recruiting·Listed Sep 2025

Apply to this trial

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

for Urothelial Cancer

Sites in Grand Rapids +7 more locations

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT07129993·Phase 2, Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

for Melanoma

Sites in Grand Rapids +5 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07115043·Phase 1, Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

for Biliary Tract Cancer

Drug: Rilvegostomig

Sites in Grand Rapids +30 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18 - 99

Code: NCT06467357·Phase 3·Recruiting·Listed Jun 2024

Apply to this trial

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

for Multiple Myeloma

Sites in Grand Rapids +10 more locations

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT05714839·Phase 1, Phase 2·Recruiting·Listed Feb 2023

Apply to this trial

A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

for Advanced Solid Tumors

Sites in Grand Rapids +3 more locations

Sponsor: ModernaTX, Inc.

Sex: All·Age: 18+

Code: NCT06880549·Phase 1·Recruiting·Listed Mar 2025

Apply to this trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

Drug: Rilvegostomig

Sites in Grand Rapids, Saginaw +63 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06692738·Phase 3·Recruiting·Listed Nov 2024

Apply to this trial

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

for Endometrial Cancer

Sites in Grand Rapids +10 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT05489211·Phase 2·Recruiting·Listed Aug 2022

Apply to this trial

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

for Non-Small Cell Lung Cancer

Drug: Rilvegostomig

Sites in Grand Rapids, Farmington Hills +47 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06357533·Phase 3·Recruiting·Listed Apr 2024

Apply to this trial

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

for Hepatocellular Carcinoma

Drug: Rilvegostomig

Sites in Grand Rapids, Detroit +29 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06921785·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

for Solid Tumors

Sites in Grand Rapids, Detroit +15 more locations

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT06431594·Phase 1·Recruiting·Listed May 2024

Apply to this trial

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

for Ovarian Neoplasms

Drug: Niraparib

Sites in Grand Rapids +8 more locations

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT04641247·Phase 2·Recruiting·Listed Nov 2020

Apply to this trial

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

for HER2-positive Gastric Cancer

Drug: Rilvegostomig

Sites in Grand Rapids, Detroit +43 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT06764875·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

for Gastric Cancer

Sites in Grand Rapids +3 more locations

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT05702229·Phase 2·Recruiting·Listed Jan 2023

Apply to this trial

Conditions in Oncology (Grand Rapids, MI)

Solid tumor· 48 Non-small cell lung cancer (NSCLC)· 30 Colorectal cancer· 28 Breast cancer· 16 Pancreatic cancer· 15 Ovarian cancer· 13 Cancer (any)· 11 Gastric cancer· 10 Bladder cancer· 10 Endometrial cancer· 9 Prostate cancer· 8 Melanoma· 8 Triple-negative breast cancer· 7 Esophageal cancer· 7 Biliary tract cancer· 6 Multiple myeloma· 6 Acute myeloid leukemia (AML)· 6 Non-Hodgkin lymphoma· 6 Hematologic malignancy· 6 Head and neck cancer· 6 Metastatic breast cancer· 5 Gastroesophageal junction cancer· 5 Kidney cancer· 5 Cervical cancer· 5 Chronic lymphocytic leukemia (CLL)· 5 Diffuse large B-cell lymphoma (DLBCL)· 5 Liver cancer· 4 Metastatic prostate cancer· 4 Sarcoma· 4 Neuroblastoma· 4 Leukemia (other)· 3 Small lymphocytic lymphoma· 3 Ewing sarcoma· 3 Small cell lung cancer· 2 Metastatic colorectal cancer· 2 Acute lymphoblastic leukemia· 2 Myelodysplastic syndromes (MDS)· 2 Hodgkin lymphoma· 2 HER2-positive breast cancer· 1 Colon cancer· 1 Rectal cancer· 1 Gastrointestinal cancer· 1 Uterine cancer· 1 Fallopian tube cancer· 1 Glioma· 1 Brain metastases· 1 Chronic myelomonocytic leukemia· 1 Myeloproliferative neoplasm· 1 Mantle cell lymphoma· 1 Burkitt lymphoma· 1 Thyroid cancer· 1 Soft tissue sarcoma· 1 Osteosarcoma· 1 Rhabdomyosarcoma· 1 Mesothelioma· 1 Neuroendocrine tumors· 1